Human Papillomavirus (HPV) Type Distribution in Adult Women Diagnosed With Invasive Cervical Cancer in New Zealand
NCT ID: NCT01328028
Last Updated: 2012-08-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
244 participants
OBSERVATIONAL
2009-04-30
2011-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Subjects diagnosed with invasive cervical cancer
Testing of archived cervical cancer tissue samples
Cervical samples will be tested for histopathology diagnosis and human papillomavirus deoxyribonucleic acid testing.
Data collection
Log sheet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Testing of archived cervical cancer tissue samples
Cervical samples will be tested for histopathology diagnosis and human papillomavirus deoxyribonucleic acid testing.
Data collection
Log sheet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histological diagnoses of invasive cervical cancer stage IB or greater, within at least the last 3 years.
* Written informed consent obtained from the subject/ next of kin/ Legally acceptable representative.
* Availability of cervical specimen on which the diagnosis was made prior to any chemotherapy or radiotherapy.
* The cervical specimen should be of appropriate size and with regular tissue specimens.
* The cervical specimen should be adequately preserved.
* All links to the subject's identity should be removed from the paraffin block.
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sykes P, Gopala K, Tan AL, Kenwright D, Petrich S, Molijn A, Chen J. Type distribution of human papillomavirus among adult women diagnosed with invasive cervical cancer (stage 1b or higher) in New Zealand. BMC Infect Dis. 2014 Jul 8;14:374. doi: 10.1186/1471-2334-14-374.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
111050
Identifier Type: -
Identifier Source: org_study_id